Cargando…

PEGylated biologics in haemophilia treatment: Current understanding of their long‐term safety

Detalles Bibliográficos
Autor principal:	Baumann, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027893/ https://www.ncbi.nlm.nih.gov/pubmed/31742794 http://dx.doi.org/10.1111/hae.13875

Ejemplares similares

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Haemophilia A associated with Down’s syndrome
por: Kaczorowska-Hac, Barbara, et al.
Publicado: (2012)

European principles of inhibitor management in patients with haemophilia: implications of new treatment options
por: Hermans, C., et al.
Publicado: (2020)

Optimal trough levels in haemophilia B: Raising expectations
por: Walsh, Christopher, et al.
Publicado: (2020)

Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment
por: Benton, Melody, et al.
Publicado: (2020)

Results of feasibility and safety of randomised controlled trial of a musculoskeletal exercise intervention versus usual care for children with haemophilia
por: Bladen, Melanie, et al.
Publicado: (2020)

Implications of haemophilia gene therapy for the changing role of the multidisciplinary team
por: Miesbach, Wolfgang, et al.
Publicado: (2021)

Three novel F8 mutations in sporadic haemophilia A cases
por: Hussain, Rashid, et al.
Publicado: (2012)

Perioperative management of a patient with haemophilia-A for major abdominal surgery
por: Sethi, Mamta, et al.
Publicado: (2017)

Autologous cell therapy – A new concept to eradicate inhibitors in haemophilia
por: Xie, Hanjing, et al.
Publicado: (2022)

Perioperative management of a patient with severe Haemophilia B for abdominal pseudotumour Surgery
por: Kumar, Lakshmi, et al.
Publicado: (2015)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
por: Iioka, F, et al.
Publicado: (2014)

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011)

Educational needs of patients, families, and healthcare professionals to support the patient journey in haemophilia gene therapy in the UK
por: Boyce, Sara, et al.
Publicado: (2023)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Response to letter to the Editors—Safety of long-term denosumab therapy
por: Stopeck, Alison T., et al.
Publicado: (2016)

Can pegylated interferon improve the outcome of polycythemia vera patients?
por: Crisà, Elena, et al.
Publicado: (2017)

Current Status of Long-term Care in Taiwan: Transition of Long-term Care Plan From 1.0 to 2.0
por: Yang, Chih-Ching, et al.
Publicado: (2019)

The Treatment of Haemophilia
por: Biggs, Rosemary
Publicado: (1969)

UK haemophilia consultant access to foot and ankle services and concurrent patient impact questionnaire responses to foot and ankle interventions
por: Wilkins, Richard A., et al.
Publicado: (2022)

Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C
por: Alkan, Erhan, et al.
Publicado: (2016)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients
por: Tacke, Frank
Publicado: (2010)

Pegylated G-CSF Combined with mFOLFIRINOX for Advanced Pancreatic Cancer Patients
por: Chen, Peng, et al.
Publicado: (2019)

Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir
por: Katiyar, Harshita, et al.
Publicado: (2023)

PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
por: Castillo, Paula M, et al.
Publicado: (2014)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Long‐term joint outcomes in adolescents with moderate or severe haemophilia A
por: Schmidt, David E., et al.
Publicado: (2022)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

Musculoskeletal treatment in haemophilia
por: Atilla, Bülent, et al.
Publicado: (2019)

Dental Treatment in Hæmophilia
por: Nicholl, B., et al.
Publicado: (1959)

Current biological and pharmacological updates on wogonin
por: Rawat, Sarita, et al.
Publicado: (2020)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'
por: Hsieh, P-Y, et al.
Publicado: (2015)

Pain relief by extracorporeal shockwave therapy: an update on the current understanding
por: Schmitz, Christoph, et al.
Publicado: (2009)

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
por: Escobar, Miguel, et al.
Publicado: (2022)

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
por: Cohn, David E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_290gl6esp48n90tnm1evqo8o47